Efficacity of Weekly Paclitaxel in Association or Not With Bevacizumab in Metastatic or Locally Advanced Angiosarcomas

Inclusion Criteria: * Angiosarcoma histologically proven * Metastatic or locally advanced and not accessible to surgery treatment * Measurable tumor with at least 1 measurable lesion, according to RECIST * For angiosarcoma in irradiated region, absence of clinical arguments of progression of the tumor prior treated by radiation * At least 28 days since the previous treatment (systemic or major surgery) * Performance Status (ECOG) ≤ 1 * Man or woman \>= 18 years * Polynuclear neutrophils \>1500/mm3, platelets \> 100 000/ mm3, Hemoglobin \> 9.0 g/dl * Total bilirubin ≤ 1.5 x USL, AST and ALT ≤ 2.5 x USL (or ≤ 5 if hepatic metastasis ) * Serum creatinin ≤ 1.5 x USL or clearance calculated \> 50 ml/mn (Cockcroft formulae) * Absence of hematuria on dipstick * Proteinuria on dipstick \<2+, if \>2, the 24 hours proteinuria must be \< 1g * Albumin \> 35 g/l and lymphocytes \> 700/mm3 attesting a life expectancy \> 3 months * Normal cardiac function : LVEF ≥ 50% * Normal coagulation test : INR ≤ 1.5 and TCA ≤ 1.5 x USL within 7 days before inclusion * Systolic BP ≤ 150 mmHg and diastolic BP ≤ 100 mmHg * Negative pregnancy test for women of reproductive potential(within 7 days before treatment start) * Effective contraceptive methods for male and female (if applicable) during the period of treatment and until the 6 months after the last administration of Bevacizumab * Adequate central veinous access * Patient covered by government health insurance * Informed consent form signed by the…